Skip to main content
CVSACovista Inc.Sell5.4·$126.30+5.06%
SellModerate Confidence
Investment thesis

Covista screens attractively valued at a forward P/E of 13.2 times and a PEG of 0.88, underpinned by four consecutive earnings beats averaging more than 11% above consensus; the chief offset is negative price momentum that has not cleared the minimum threshold, keeping the entry setup cautious despite sound fundamentals.

Thesis pillars

  • Negative Momentum Near Term HeadwindImproving
  • Attractive Forward Valuation Low PegDeteriorating
  • Solid Piotroski Financial HealthStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Covista Inc. (CVSA) Stock Analysis

Range Bound setup · Catalyst-Driven edge

SellVALUE-TRAP 1/5QualityModerate Confidence

Consumer Defensive · Education & Training Services

Sell if holding. At $126.30, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.2%; Weak growth.

Adtalem is the leading healthcare educator in the U.S. and a systemically important solution for preparing a diverse talent workforce that meets the needs of the healthcare industry. The purpose of Adtalem is to empower students to achieve their goals, find success, and make... Read more

$126.30+5.2% A.UpsideScore 5.4/10#14 of 18 Education & Training Services
QualityF-score7 / 9FCF yield6.72%
Stop $117.46Target $132.81(analyst − 15%)A.R:R 0.4:1
Analyst target$156.25+23.7%4 analysts
$132.81our TP
$126.30price
$156.25mean
$175

Sell if holding. At $126.30, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.2%; Weak growth. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.

Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Aug 6, 20269d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Thin upside margin: 5.2%
Weak growth

Key Metrics

P/E (TTM)17.5
P/E (Fwd)13.5
Mkt Cap$4.1B
EV/EBITDA11.0
Profit Mgn12.3%
ROE17.9%
Rev Growth4.5%
Beta0.62
DividendNone
Rating analysts10

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.23bullish
IV71%elevated
Max Pain$160+26.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
3.6
GatesA.R:R 0.4 < 1.5@spotMomentum 5.3<5.5 (soft — BUY_NOW allowed but watch)EARNINGS PROXIMITY 9d<=14d (soft)Momentum 5.3>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
45 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $109.42Resistance $135.96

Price Targets

$117
$133
A.Upside+5.2%
A.R:R0.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! asymmetry at 0.4 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (9d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CVSA stock a buy right now?

Sell if holding. At $126.30, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 5.2%; Weak growth. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $117.46. Score 5.4/10, moderate confidence.

What is the CVSA stock price target?

Take-profit target: $132.81 (+5.2% upside). Prior stop was $117.46. Stop-loss: $117.46.

What are the risks of investing in CVSA?

Thin upside margin: 5.2%; Weak growth.

Is CVSA overvalued or undervalued?

Covista Inc. trades at a P/E of 17.5 (forward 13.5). TrendMatrix value score: 7.3/10. Verdict: Sell.

What do analysts say about CVSA?

10 analysts cover CVSA with a consensus score of 4.3/5. Average price target: $156.

What does Covista Inc. do?Adtalem is the leading healthcare educator in the U.S. and a systemically important solution for preparing a diverse...

Adtalem is the leading healthcare educator in the U.S. and a systemically important solution for preparing a diverse talent workforce that meets the needs of the healthcare industry. The purpose of Adtalem is to empower students to achieve their goals, find success, and make inspiring contributions to our global community.

Related stocks: TAL (TAL Education Group) · PXED (Phoenix Education Partners, Inc) · EDU (New Oriental Education & Techno) · PRDO (Perdoceo Education Corporation) · LOPE (Grand Canyon Education, Inc.)
Home Stocks CVSA

Latest news

Latest News

Newser92d ago
MSN78d ago
Yahoo Finance78d ago
StockStory86d agoEarnings
Yahoo Finance79d ago
Yahoo Finance79d ago
CDLLife86d ago
FreightWaves91d ago
Yahoo Finance77d ago
StockStory84d ago
TradingView84d ago
Marketscreener.com84d agoEarnings
Marketscreener.com84d agoEarnings
Business Wire84d agoEarnings
Investing.com South Africa84d agoEarnings
Simplywall.st81d ago
Timothysykes.com81d ago
GuruFocus104d ago
Timothysykes.com82d agoProduct
GuruFocus83d ago
Loading more...